ImmunArray will use Quanterix's Simoa single-molecule array technology for biomarker analysis, with the potential to enrich its diagnostic panels.
The company will develop the assays for its single-molecule array technology and incorporate the markers into multiplex assays for research use in neurology.
Three new investors joined existing investors in leading the round, which will fund desktop instrument development, international sales, and assay menu expansion.
As Quanterix continues to grow its business, quantifying proteins in single cells could drive its sales in the academic market, CEO Kevin Hrusovsky said.
The firm has signed an exclusive agreement for China with Cold Spring Biotech and a deal for Singapore, Thailand, and Malaysia with Research Instruments.
The firm has re-engineered hardware and redesigned software to improve its single-molecule array platform and has increased its multiplexing capabilities.
Quanterix has won a second GE NFL Head Health Challenge I grant and will use it to develop diagnostics with biomarkers discovered under the first grant.
Leveraging Quanterix's Simoa technology, PBL will be able to enter new markets and strengthen its current product offerings.
The genome editing nucleases slide and hop along double-stranded DNA to find and bind to their target sequence.
Myriad RBM has manufactured and validated immunoassays based on Quanterix's single molecule array technology, Simoa.
In Science this week: intellectual property landscape of CRISPR genome editing, and more.
A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.
Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.
Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.